Patrick Campbell

The July 2024 endocrinology month in review recaps a pair of regulatory updates, multiple studies on incretin therapies, and the most recent episodes of our flagship diabetes podcast, Diabetes Dialogue.

The July 2024 cardiology month in review spotlights new data from obicetrapib, a deep dive into risk stratification algorithms, and studies on the need for optimal care.

An analysis of more than 11,000 people with T1D found people were more likely to report an affected father than an affected mother.

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

Trust in physicians and hospitals dropped from over 70% in 2020 to under 50% in 2024, with declines seen across all demographics, a new survey shows.

A study cautions the AHA's new PREVENT equations may underprescribe statins and antihypertensives, potentially causing 107,000 more ASCVD events in 10 years.

New study finds semaglutide may reduce smoking urge in type 2 diabetes patients, decreasing tobacco use disorder medical encounters by up to 32%.

The phase 3 trial suggest obicetrapib offered significant reductions in LDL-C when added to maximally tolerated lipid-lowering therapy in HeFH.

A recap of the 5 most popular topics related to gene therapy in ophthalmology coming from the 42nd American Society of Retina Specialists meeting.

Brett King, MD, PhD, discusses how the deuruxolitinib approval impacts the treatment landscape of alopecia areata.

Personalized text messages can boost physical activity in cardiac rehab patients, especially in early stages, but effectiveness varies by time and device, study finds.

UAB research shows AHA’s Life’s Essential 8 and Simple 7 scores aid public health but are less effective than pooled cohort equations for predicting individual cardiovascular risk.

Despite recommendations, an analysis of more than 3.2 million youths suggests fewer than 15% of children/adolescents receive lipid screening.

An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.

An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.

The XTEND-Kids phase 3 trial shows efanesoctocog alfa’s safety and efficacy in children with severe hemophilia A, reducing bleeds with once-weekly dosing.

The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.

A study found omega-3 supplements and a Mediterranean diet improved acne severity and quality of life in patients without prescription meds.

Promoting adherence to a Mediterranean diet in children improves cardiometabolic health biomarkers, according to a new study.

A STEP-HFpEF analysis suggests semaglutide 2.4 mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF.

Study finds women with familial hypercholesterolemia receive less intensive treatment and are less likely to achieve LDL-C goals than men.

An analysis of CLEAR Outcomes and CTTC data suggest bempedoic acid holds its own relative to statin therapy for cardiovascular risk reduction normalized to 1 mmol/L reduction in LDL-C.

Arcutis Biotherapeutics announced the update and indicated the FDA was working to finalize the action letter on July 09, 2024, which was 2 days after the assigned PDUFA date of July 07, 2024.

A study of 18,000 patients showed tirzepatide (Mounjaro) led to more significant weight loss than semaglutide (Ozempic) in adults with overweight or obesity.

Announced by Genentech on July 04, 2024, the prefilled, 6.0 mg syringe is designed to improve ease of administration and offer ophthalmologists with a ready-to-use version of the bispecific antibody.

In the endocrinology month in review, we spotlight top news in the endocrinology pipeline and the most important updates from ADA 2024.